An APTT prolongation factor estimation system includes one or more facilities each including an analyzer which measures a blood coagulation reaction of a subject blood specimen, a database which stores data on a blood coagulation reaction and APTT prolongation factor of blood specimens, and a computer which estimates an APTT prolongation factor of the subject blood specimen based on the data on the blood coagulation reaction from the analyzer and the data stored in the database. The facilities each further includes a data transmission unit which transmits, to the computer, the data on the blood coagulation reaction of the subject blood specimen obtained by the analyzer, and a data reception unit which receives a result of the estimation of the APTT prolongation factor, which is obtained by the computer, regarding the subject blood specimen measured by each of the analyzers.

An APTT prolongation factor estimation system includes one or more facilities each including an analyzer which measures a blood coagulation reaction of a subject blood specimen, a database which stores data on a blood coagulation reaction and APTT prolongation factor of blood specimens, and a computer which estimates an APTT prolongation factor of the subject blood specimen based on the data on the blood coagulation reaction from the analyzer and the data stored in the database. The facilities each further includes a data transmission unit which transmits, to the computer, the data on the blood coagulation reaction of the subject blood specimen obtained by the analyzer, and a data reception unit which receives a result of the estimation of the APTT prolongation factor, which is obtained by the computer, regarding the subject blood specimen measured by each of the analyzers.

Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. The methods can be used to facilitate determining a dosage or heparin or ATIII to administer to a patient.

Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. The methods can be used to facilitate determining a dosage or heparin or ATIII to administer to a patient.

This invention relates to a method and apparatus for determining the activity of coagulation factors in dilute capillary whole blood, citrated whole blood and citrated plasma. It also includes the detection of the hemoglobin amount in a whole blood sample so a correction of the clotting time can be performed thereby making the clotting time values independent of hemoglobin and hematocrit effect.

This invention relates to a method and apparatus for determining the activity of coagulation factors in dilute capillary whole blood, citrated whole blood and citrated plasma. It also includes the detection of the hemoglobin amount in a whole blood sample so a correction of the clotting time can be performed thereby making the clotting time values independent of hemoglobin and hematocrit effect.

Disclosed herein is a method of providing a metabololipidomic profile and SPM signature on the progress of the innate host defense response following blood clotting. The method can include the step of taking one or more measurements in a patient's blood sample, wherein the sample is obtained during the time-course of clotting or coagulation or following clotting or coagulation, of pro-thrombotic and pro-inflammatory mediators (eicosanoids) and specialized pro-resolving mediators SPMs. From these measurements, a personalized metabololipidomic profile can be obtained. By comparing the measurement to that taken from normal or reference blood, a comparison profile can be developed. The profile comparison profile can then be used to make a medical or therapeutic decision.

Disclosed herein is a method of providing a metabololipidomic profile and SPM signature on the progress of the innate host defense response following blood clotting. The method can include the step of taking one or more measurements in a patient's blood sample, wherein the sample is obtained during the time-course of clotting or coagulation or following clotting or coagulation, of pro-thrombotic and pro-inflammatory mediators (eicosanoids) and specialized pro-resolving mediators SPMs. From these measurements, a personalized metabololipidomic profile can be obtained. By comparing the measurement to that taken from normal or reference blood, a comparison profile can be developed. The profile comparison profile can then be used to make a medical or therapeutic decision.

Disclosed are an immunochemical assay device and a method of using the immunochemical assay device for detecting one or more targets or markers such as Cardiac Troponin I, NT-pro-BNP, D-dimer and/or cross-linked fibrin in a fluid sample.

Disclosed are an immunochemical assay device and a method of using the immunochemical assay device for detecting one or more targets or markers such as Cardiac Troponin I, NT-pro-BNP, D-dimer and/or cross-linked fibrin in a fluid sample.